June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Mineralocorticoid Receptor Antagonism in the Treatment of Chronic Central Serous Chorioretinopathy: First Pilot Study
Author Affiliations & Notes
  • Min Zhao
    CRC, Inserm U872, Team 17, Paris, France
    Université René Descartes Sorbonne, Paris, France
  • Elodie Bousquet
    CRC, Inserm U872, Team 17, Paris, France
    Université René Descartes Sorbonne, Paris, France
  • Francine Behar-Cohen
    CRC, Inserm U872, Team 17, Paris, France
    Department of Ophthalmology, Hôtel-Dieu Hospital, AP-HP, Paris, France
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2813. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Min Zhao, Elodie Bousquet, Francine Behar-Cohen; Mineralocorticoid Receptor Antagonism in the Treatment of Chronic Central Serous Chorioretinopathy: First Pilot Study. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2813.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Based on experimental data showing that central serous chorioretinopathy (CSC) could result from over-activation of mineralocorticoid receptor (MR) pathway in choroid vessels, we studied a MR antagonist, eplerenone, as a potential treatment for chronic CSC.

Methods: Thirteen patients with chronic CSC were included in a pilot prospective study. Patients were treated with oral eplerenone 25 mg/day for a week followed by 50 mg/day for 1 or 3 months. The primary outcome measure was the change in central macular thickness (CMT) recorded by optical coherence tomography (OCT) at 1 and 3 months after eplerenone treatment. The secondary outcomes included changes in foveal subretinal fluid (SRF) measured by OCT and in best-corrected visual acuity (BVCA) at 1 and 3 months after eplerenone treatment.

Results: CMT decreased significantly from 352±139 μm at baseline, to 246±113 μm and 189±99 μm at 1 and 3 months under eplerenone treatment (p<0.05 and p<0.01, respectively). The SRF level at 3 months was significantly decreased compared with baseline SRF (p<0.01). BVCA at 3 months was significantly improved compared with baseline BVCA (p<0.001). The treatment was well tolerated.

Conclusions: Eplerenone treatment was associated with a significant reduction in central macular thickness, subretinal fluid level and an improvement in visual acuity. Randomized controlled trials are needed to confirm these encouraging results.

Keywords: 462 clinical (human) or epidemiologic studies: outcomes/complications • 550 imaging/image analysis: clinical • 452 choroid  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×